SF 5162 (2025-2026) – Summary
Overview and purpose
- Jurisdiction: Minnesota
- Session: 2025-2026
- Chief theme: Reorganizes regulatory responsibilities across health plans and financial institutions; eliminates the Prescription Drug Affordability Advisory Council; makes targeted modifications to various financial, health plan, and regulatory provisions; includes appropriations and expenditures adjustments.
- Status: Referred to Health and Human Services (as introduced). Article 1 focuses on Commerce/Finance shifts; Article 2 on Prescription Drug Affordability Advisory Council; Article 3 on Non-depository Institutions; Article 4 on Health Plan Regulatory Alignment.
Key provisions and changes
Article 1 – Commerce Finance
- Appropriation and transfer of regulatory duties:
- Sec. 1: $1,750,000 in FY 2027 from the General Fund to the Commissioner of Commerce to regulate health maintenance organizations (HMOs) and county-based purchasers.
- Sec. 2: Requires a coordination-based budget reduction: Department of Health’s FY 2027 general fund and state government special revenue allocations reduced by $1,750,000 and $1,836,000 respectively to reflect transfer of HMO/county-based purchaser regulatory responsibilities to the Commissioner of Commerce. Reductions are ongoing.
- Practical effect: HMO and certain purchaser regulatory activities move from Health to Commerce, with corresponding budget realignment.
Article 2 – Prescription Drug Affordability Advisory Council
- Expanded conflict-of-interest and disclosure rules for board/council members:
- Subd. 1 (Sec. 1): Redefines “conflict of interest” to include financial/personal associations that bias or appear biased, including immediate family and in-laws with substantial financial benefit related to board actions.
- Subd. 2 (Sec. 2): Requires early disclosure of conflicts before first meeting after identification, and mandatory recusal for discussions/reviews involving affected drug products.
- Criteria for identifying prescription drug products:
- Sec. 3: Board, with advisory council and Health Commissioner, must identify certain prescription products based on price growth, high WAC (wholesale acquisition cost) thresholds, biosimilar price differentials, and high generic WAC thresholds. Specific criteria include:
- Brand drugs/biologics with WAC up >15% or >$3,000 (12-month lookback, CPI-adjusted)
- Brand drugs/biologics with WAC ≥ $60,000 per year or per course
- Biosimilars not at least 20% cheaper than referenced biologic at introduction
- Generics with WAC ≥ $100 for 30-day/short course/unit, or price increases ≥200% in prior 12 months
- Public data and confidentiality:
- Sec. 3(b): List of identified products and related price information to be made public, with exemptions for proprietary information and trade secrets per standards set by the board and applicable data classifications.
- Repeal of certain statutes:
- Sec. 4: Repeals Minnesota Statutes 2024, sections 62J.86(2) and 62J.88.
Article 3 – Non-depository Institutions
- Broad updates to licensing and authority for non-depository financial institutions:
- Sec. 1: Revisions to general authority for various lenders and mortgage-related entities (banks, savings banks, trust companies, mortgage originators/servicers, etc.) to make loans or purchase obligations, including those insured/guaranteed by HUD, Veterans Affairs, Farmers Home Administration, and government-sponsored entities (Fannie Mae, Freddie Mac).
- Definitions and license-related updates:
- Secs. 2-8: Revisions to definitions (e.g., APR, borrower, loan, credit, financial charges) and licensing provisions for various loan types, small consumer loans, and collateralized loans.
- Sec. 9-12: Updates to license postings, registration, and related regulatory framework for virtual currency activities, debt modules (debt management services and debt settlement services), and replacement/supplemental regulatory routes.
- Repeal of certain sections:
- Sec. 15: Repeals sections 56.08; 332A.02(2); 332B.02(2).
Article 4 – Health Plan Regulatory Alignment
- Substantial alignment provisions between Commerce and Health for health plans:
- Sec. 1: 60A.071 – Substantial Enrollment Growth notification:
- By April 15 annually, large health plans (with ≥25,000 enrollees) must notify the Commissioner if enrollment growth thresholds are met or exceeded (growth >35% since last year or line-specific growth thresholds).
- Commissioner may request additional information about financial readiness, projections (3-year), key assumptions, risk, assets, surplus, reinsurance, etc.
- Sec. 2-13: Various cross-regulatory adjustments to sections involving loss ratio standards, rate filings, and disclosures for health plans, aligning rules between commerce and health departments.
- Sec. 14-16: Loss ratio requirements and cessation of individual market business:
- Establishes reporting, loss ratio targets, and a public-facing dashboard of actual loss ratios by health plan company.
- Provisions for short-term coverage and its interaction with loss ratio requirements; limits on short-term plan duration and renewal rules.
- Provisions governing cessation of individual health plan market and required notice to policyholders, with guidance about MNsure reporting and consumer access.
- Sec. 17-18: Transfer of regulatory duties for HMOs from Health to Commerce; transfer mechanics, employee transition, and protections for transferred workers.
- Sec. 19-20: HMOs’ annual reporting and data requirements to the respective commissioners and alignment of reporting obligations.
Who would be affected
- Health Maintenance Organizations (HMOs) and county-based health purchasers: Regulatory oversight shifts from Minnesota Department of Health to Minnesota Department of Commerce (transfer effective date noted; accompanying staffing and budget impacts).
- Health plan issuers and carriers: Subject to new or aligned supervision provisions, enrollment-growth notifications, loss ratio reporting, and MNsure certification requirements.
- Non-depository financial institutions: Banks, savings institutions, mortgage originators/servicers, and other lenders; expanded licensing, registration, and reporting obligations; more robust oversight of virtual currency activities and debt management services providers; potential changes in compliance costs.
- Debt management and debt settlement services providers: New/revised forms, registration processes, and oversight.
- State agencies and state employees: Reallocation of duties and potential workforce transitions between Health and Commerce; ongoing cost adjustments.
Procedural and timeline notes
- Transfer of HMO regulation duties from Health to Commerce targeted for July 1, 2026 (Article 4, Sec. 17).
- FY2027 budget adjustments: Transfers create ongoing reductions in Department of Health appropriations to reflect new responsibilities (Articles 1 and 4 contemplate phased budget realignments in FY2027 onward).
- Enrollee growth notifications trigger reporting and potential corrective actions; joint or coordinated public release of loss ratio data by Commerce and Health (Article 4, Sec. 13-14).
- Repeals and consolidations: Elimination of the Prescription Drug Affordability Advisory Council (Article 2) and repeal of specified statutory sections (Sec. 4).
dollar amounts, dates, and percentages
- Appropriation: $1,750,000 in FY 2027 to Commerce for HMO/county-based purchaser regulation (Sec. 1).
- Adjusted appropriations: Health Department general fund and state government special revenue reductions of $1,750,000 and $1,836,000 respectively (Sec. 2).
- Enrollment growth trigger: 35% growth threshold or line-specific threshold (Article 4, Sec. 1).
- Loss ratio targets and schedules: Specific loss ratio targets and phased-in adjustments described (Article 4, Sec. 13).
Summary assessment
SF 5162 is a comprehensive reorganization and modernization bill that:
- Eliminates the Prescription Drug Affordability Advisory Council and formalizes conflict-of-interest standards.
- Moves HMO and county-based purchaser regulatory oversight from Health to Commerce, with corresponding budget realignments.
- Expands and hardens regulatory definitions/requirements for non-depository financial institutions, debt management/settlement services, and virtual currency activities.
- Aligns health plan regulation between Commerce and Health, including strict enrollment-growth monitoring, loss ratio reporting, and public data transparency, while establishing a clear transfer path for HMOs and related staff.
- Establishes procedural timelines and reporting obligations to improve preparedness, transparency, and accountability.
